Gemtuzumab ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia

Keyphrases

• Adverse Events 12%
• Am(III) 12%
• AML Relapse 12%
• Anaphylactic Reaction 12%
• Calicheamicin 12%
• Catecholamines 12%
• CD33 12%
• CD33 Antibody 12%
• Compassionate Use 12%
• Conventional Treatment 12%
• Cytotoxic Agents 12%
• Defibrotide 12%
• First Remission 12%
• Gemtuzumab Ozogamicin 100%
• Immunoconjugate 12%
• Intensive Care 12%
• Mylotarg 100%
• Pegylated Liposomal Doxorubicin 12%
• Refractory AML 12%
• Relapse Prevention 12%
• Relapsed AML 12%
• Relapsed or Refractory Acute Myeloid Leukemia 100%
• Relapsed or Refractory AML 12%
• Reoccurrence 12%
• Second Remission 12%
• Secondary AML 12%
• Stem Cell Transplantation 25%
• Supportive Care Needs 12%
• Systemic Hypotension 12%
• Targeted Treatment 12%
• Treatment Options 12%
• Veno-occlusive Disease of the Liver 12%

Medicine and Dentistry

• Acute Myelogenous Leukemia 77%
• Acute Myeloid Leukemia 100%
• Adverse Event 11%
• Anaphylaxis 11%
• Calicheamicin 11%
• Catecholamine 11%
• Compassionate Use 11%
• Cytotoxic Agent 11%
• Defibrotide 11%
• Gemtuzumab Ozogamicin 100%
• Hypotension 11%
• Intensive Care 11%
• Liposomal Daunorubicin 11%
• Secondary Acute Myeloid Leukemia 11%
• Side Effect 22%
• Stem Cell Therapy 22%
• Targeted Therapy 11%
• Vein Occlusion 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Adverse Event 11%
• Anaphylaxis 11%
• Calicheamicin 11%
• Catecholamine 11%
• Cytotoxic Agent 11%
• Daunorubicin 11%
• Defibrotide 11%
• Gemtuzumab Ozogamicin 100%
• Hypotension 11%
• Remission 22%
• Secondary Acute Myeloid Leukemia 11%
• Side Effect 22%
• Vein Occlusion 11%